| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.00085 | 1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00089 | 1 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.0036 | 1 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.00094 | 1 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.00076 | 1 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.00074 | 1 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.00053 | 1 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | -0.00051 | 1 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.00064 | 1 |